Cognitive-affective manifestations since premanifest phases of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease

被引:1
|
作者
Bolzan, Gabriela [1 ,2 ]
Eyng, Maria E. Mueller [3 ]
Leotti, Vanessa B. [4 ,5 ]
Saraiva-Pereira, Maria L. [1 ,6 ,7 ]
Jardim, Laura B. [1 ,6 ,8 ,9 ]
机构
[1] Univ Fed Rio Grande do Sul, Programa Posgrad Genet & Biol Mol, Porto Alegre, Brazil
[2] Hosp Clin Porto Alegre, Ctr Pesquisa Clin & Expt, Porto Alegre, Brazil
[3] Univ Fed Rio Grande do Sul, Fac Med, Porto Alegre, Brazil
[4] Univ Fed Rio Grande do Sul, Dept Estat, Porto Alegre, Brazil
[5] Univ Fed Rio Grande do Sul, Programa Posgrad Epidemiol, Porto Alegre, Brazil
[6] Hosp Clin Porto Alegre, Serv Genet Med, Rua Ramiro Barcelos 2350, BR-90035003 Porto Alegre, Brazil
[7] Univ Fed Rio Grande do Sul, Dept Bioquim, Porto Alegre, Brazil
[8] Univ Fed Rio Grande do Sul, Dept Med Interna, Porto Alegre, Brazil
[9] Hosp Clin Porto Alegre, DMI FAMED UFRGS, Rua Ramiro Barcelos 2350, BR-90035003 Porto Alegre, Brazil
关键词
Cerebellar Cognitive Affective; Schmahmann Syndrome; Spinocerebellar Ataxia Type 3; Machado-Joseph Disease; Cognition; Affect; MACHADO-JOSEPH-DISEASE; NEUROPATHOLOGY; DYSFUNCTION; SCALE; MIND;
D O I
10.1016/j.cortex.2023.09.021
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Background: Cognitive deficits were related to Spinocerebellar Ataxia type 3/MachadoJoseph Disease (SCA3/MJD), but the Cerebellar Cognitive Affective Syndrome (CCAS) needs further investigation in this disorder. We aimed to characterize cognitive-affective deficits in manifest and premanifest SCA3/MJD carriers.Methods: Subjects at 50% risk, manifest carriers and unrelated controls were evaluated inperson or in virtual settings with CCAS Scale (CCAS-S), Stroop Color-Word Test (SCWT), Trail-Making Test (TMT), and Reading the Mind in the Eyes Test (RMET). Scale for Assessment and Rating of Ataxia (SARA) >2.5 or Friedreich Ataxia Rating Scale/Activities of Daily Living (FARS-adl) >4 divided carriers into manifest and premanifest. Time after onset or time left to gait ataxia onset (TimeToAfterOnset) were estimated. Differences between groups and correlations with TimeToAfterOnset, SARA and FARS-adl were checked.Results: After random selection to balance groups, 23 manifest and 35 premanifest carriers, and 58 controls were included. CCAS-S, semantic fluency, phonemic fluency, category switching, affect, SCWT, and RMET showed significant differences between manifest carriers and controls; premanifest carriers mostly displayed intermediate values between controls and manifest carriers. These variables correlated with TimeToAfterOnset and SARA scores of the carriers. Correlations with SARA were stronger in the pre-ataxic group. CCAS-S had the strongest correlations with time and SARA. Discussion: Cognitive-affective deficits in SCA3/MJD involve executive function, language, affect, and social cognition, which seem to be altered prior to the ataxia onset, and correlate with markers of motor progression. CCAS-S was the most promising biomarker and should be evaluated in longitudinal studies.(c) 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页码:370 / 382
页数:13
相关论文
共 50 条
  • [1] Spinocerebellar ataxia type 3 (Machado-Joseph disease)
    Dulski, Jaroslaw
    Al-Shaikh, Rana Hanna
    Sulek, Anna
    Kasprzak, Jakub
    Slawek, Jaroslaw
    Wszolek, Zbigniew K.
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2022, 132 (10):
  • [2] The Neuropathology of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease
    Koeppen, Arnulf H.
    POLYGLUTAMINE DISORDERS, 2018, 1049 : 233 - 241
  • [3] Quality of Life since Pre-Ataxic Phases of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease
    Bolzan, Gabriela
    Leotti, Vanessa Bielefeldt
    de Oliveira, Camila Maria
    Ecco, Gabriela
    Cappelli, Amanda Henz
    Rocha, Anastacia Guimaraes
    Kersting, Nathalia
    Rieck, Mariana
    de Sena, Lucas Schenatto
    Martins, Ana Carolina
    Saraiva-Pereira, Maria-Luiza
    Jardim, Laura Bannach
    CEREBELLUM, 2022, 21 (02): : 297 - 305
  • [4] Spinocerebellar ataxia type 3 (Machado-Joseph disease) and varenicline
    Young, Pablo
    Finn, Barbara C.
    Giuliani, Franco
    Reisin, Ricardo
    REVISTA MEDICA DE CHILE, 2015, 143 (09) : 1221 - 1222
  • [5] Mouse Models of Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)
    Colomer Gould, Veronica F.
    NEUROTHERAPEUTICS, 2012, 9 (02) : 285 - 296
  • [6] A new classification of spinocerebellar ataxia type 3 (Machado-Joseph disease)
    Teive, HA
    Arruda, WO
    Werneck, LC
    MOVEMENT DISORDERS, 2004, 19 : S25 - S25
  • [7] Diagnosis of Spinocerebellar Ataxia type 3 (Machado-Joseph disease) in Chile
    Miranda C, Marcelo
    REVISTA MEDICA DE CHILE, 2015, 143 (01) : 126 - 127
  • [8] Mouse Models of Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)
    Veronica F. Colomer Gould
    Neurotherapeutics, 2012, 9 : 285 - 296
  • [9] Spinocerebellar ataxia type 3/Machado-Joseph disease starting before adolescence
    Donis, Karina Carvalho
    Morales Saute, Jonas Alex
    Krum-Santos, Ana Carolina
    Furtado, Gabriel Vasata
    Mattos, Eduardo Preusser
    Saraiva-Pereira, Maria Luiza
    Torman, Vanessa Leotti
    Jardim, Laura Bannach
    NEUROGENETICS, 2016, 17 (02) : 107 - 113
  • [10] First report on spinocerebellar ataxia type 3 (Machado-Joseph disease) in Poland
    Dulski, Jaroslaw
    Al-Shaikh, Rana Hanna
    Sulek, Anna
    Kasprzak, Jakub
    Slawek, Jaroslaw
    Wszolek, Zbigniew K.
    PARKINSONISM & RELATED DISORDERS, 2022, 105 : 39 - 42